Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up

Detalhes bibliográficos
Autor(a) principal: Santos, Rafael G. Dos
Data de Publicação: 2018
Outros Autores: Sanches, Rafael Faria, Osório, Flávia de Lima, Hallak, Jaime E. C.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Archives of Clinical Psychiatry
Texto Completo: https://www.revistas.usp.br/acp/article/view/144883
Resumo: Background Ayahuasca is a botanical hallucinogenic preparation traditionally used by indigenous populations of Northwestern Amazonian countries for ritual and therapeutic purposes. It is rich in β-carboline alkaloids and N,N-dimethyltryptamine (DMT). Preclinical, observational, and experimental studies suggest that ayahuasca and its alkaloids have anxiolytic and antidepressive effects. We recently reported in an open-label trial that ayahuasca administration was associated with significant decreases in depression symptoms for 2-3 weeks after the experimental session in 17 patients with treatment-resistant major depressive disorder. Objectives To investigate if the experiment had any long-lasting effects on patients Methods Eight patients were interviewed 4 to 7 years after ayahuasca intake. Results Our results suggest that ayahuasca was well tolerated and that symptom reductions were limited to a few weeks. Importantly, most patients believed that the experience was among the most important of their lives, even 4-7 years later. Discussion To the best of our knowledge, this is the first long-term follow-up of a clinical sample that participated in an ayahuasca trial. Further studies with different and repeated dosing should be designed to further explore the antidepressive and anxiolytic effects of ayahuasca.
id USP-5_f36b9397668cdc3d3e9e7431b9babca0
oai_identifier_str oai:revistas.usp.br:article/144883
network_acronym_str USP-5
network_name_str Archives of Clinical Psychiatry
repository_id_str
spelling Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-upHallucinogenspsychedelicsayahuascadepressionsafety Background Ayahuasca is a botanical hallucinogenic preparation traditionally used by indigenous populations of Northwestern Amazonian countries for ritual and therapeutic purposes. It is rich in β-carboline alkaloids and N,N-dimethyltryptamine (DMT). Preclinical, observational, and experimental studies suggest that ayahuasca and its alkaloids have anxiolytic and antidepressive effects. We recently reported in an open-label trial that ayahuasca administration was associated with significant decreases in depression symptoms for 2-3 weeks after the experimental session in 17 patients with treatment-resistant major depressive disorder. Objectives To investigate if the experiment had any long-lasting effects on patients Methods Eight patients were interviewed 4 to 7 years after ayahuasca intake. Results Our results suggest that ayahuasca was well tolerated and that symptom reductions were limited to a few weeks. Importantly, most patients believed that the experience was among the most important of their lives, even 4-7 years later. Discussion To the best of our knowledge, this is the first long-term follow-up of a clinical sample that participated in an ayahuasca trial. Further studies with different and repeated dosing should be designed to further explore the antidepressive and anxiolytic effects of ayahuasca.Universidade de São Paulo. Faculdade de Medicina. Instituto de Psiquiatria2018-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/acp/article/view/14488310.1590/0101-60830000000149Archives of Clinical Psychiatry; v. 45 n. 1 (2018); 22-24Archives of Clinical Psychiatry; Vol. 45 No. 1 (2018); 22-24Revista de Psiquiatria Clínica; Vol. 45 Núm. 1 (2018); 22-241806-938X0101-6083reponame:Archives of Clinical Psychiatryinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/acp/article/view/144883/139110Copyright (c) 2018 Archives of Clinical Psychiatryinfo:eu-repo/semantics/openAccessSantos, Rafael G. DosSanches, Rafael FariaOsório, Flávia de LimaHallak, Jaime E. C.2018-03-29T16:34:04Zoai:revistas.usp.br:article/144883Revistahttp://www.hcnet.usp.br/ipq/revista/index.htmlPUBhttps://old.scielo.br/oai/scielo-oai.php||archives@usp.br1806-938X0101-6083opendoar:2018-03-29T16:34:04Archives of Clinical Psychiatry - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up
title Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up
spellingShingle Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up
Santos, Rafael G. Dos
Hallucinogens
psychedelics
ayahuasca
depression
safety
title_short Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up
title_full Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up
title_fullStr Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up
title_full_unstemmed Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up
title_sort Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up
author Santos, Rafael G. Dos
author_facet Santos, Rafael G. Dos
Sanches, Rafael Faria
Osório, Flávia de Lima
Hallak, Jaime E. C.
author_role author
author2 Sanches, Rafael Faria
Osório, Flávia de Lima
Hallak, Jaime E. C.
author2_role author
author
author
dc.contributor.author.fl_str_mv Santos, Rafael G. Dos
Sanches, Rafael Faria
Osório, Flávia de Lima
Hallak, Jaime E. C.
dc.subject.por.fl_str_mv Hallucinogens
psychedelics
ayahuasca
depression
safety
topic Hallucinogens
psychedelics
ayahuasca
depression
safety
description Background Ayahuasca is a botanical hallucinogenic preparation traditionally used by indigenous populations of Northwestern Amazonian countries for ritual and therapeutic purposes. It is rich in β-carboline alkaloids and N,N-dimethyltryptamine (DMT). Preclinical, observational, and experimental studies suggest that ayahuasca and its alkaloids have anxiolytic and antidepressive effects. We recently reported in an open-label trial that ayahuasca administration was associated with significant decreases in depression symptoms for 2-3 weeks after the experimental session in 17 patients with treatment-resistant major depressive disorder. Objectives To investigate if the experiment had any long-lasting effects on patients Methods Eight patients were interviewed 4 to 7 years after ayahuasca intake. Results Our results suggest that ayahuasca was well tolerated and that symptom reductions were limited to a few weeks. Importantly, most patients believed that the experience was among the most important of their lives, even 4-7 years later. Discussion To the best of our knowledge, this is the first long-term follow-up of a clinical sample that participated in an ayahuasca trial. Further studies with different and repeated dosing should be designed to further explore the antidepressive and anxiolytic effects of ayahuasca.
publishDate 2018
dc.date.none.fl_str_mv 2018-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/acp/article/view/144883
10.1590/0101-60830000000149
url https://www.revistas.usp.br/acp/article/view/144883
identifier_str_mv 10.1590/0101-60830000000149
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/acp/article/view/144883/139110
dc.rights.driver.fl_str_mv Copyright (c) 2018 Archives of Clinical Psychiatry
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2018 Archives of Clinical Psychiatry
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Medicina. Instituto de Psiquiatria
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Medicina. Instituto de Psiquiatria
dc.source.none.fl_str_mv Archives of Clinical Psychiatry; v. 45 n. 1 (2018); 22-24
Archives of Clinical Psychiatry; Vol. 45 No. 1 (2018); 22-24
Revista de Psiquiatria Clínica; Vol. 45 Núm. 1 (2018); 22-24
1806-938X
0101-6083
reponame:Archives of Clinical Psychiatry
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Archives of Clinical Psychiatry
collection Archives of Clinical Psychiatry
repository.name.fl_str_mv Archives of Clinical Psychiatry - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||archives@usp.br
_version_ 1800237624175099904